about
Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injuryBiomarkers and mechanisms of drug-induced vascular injury in non-rodents.Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury.The role of caveolae in the pathophysiology of lung diseases.Drug safety testing paradigm, current progress and future challenges: an overview.Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.Comparison of the endothelial toxicity induced by short-term amiodarone and diazepam exposure in a human umbilical vein endothelial cell line (EVC304).A bilayer small diameter in vitro vascular model for evaluation of drug induced vascular injuryEvidence for the nitric oxide pathway as a potential mode of action in fenoldopam-induced vascular injury.Coronary and systemic arterial physiology and immunohistochemical markers related to early coronary arterial lesions in beagle dogs given the potassium channel opener, ZD6169, or the endothelin receptor antagonist, ZD1611.Effect of two lipid emulsions on reversing high-dose levobupivacaine-induced reduced vasoconstriction in the rat aortas.Translation strategy for the qualification of drug-induced vascular injury biomarkers.Spontaneous lesions of the cardiovascular system in purpose-bred laboratory nonhuman primates.Regional myocardial ischemia-induced activation of MAPKs is associated with subcellular redistribution of caveolin and cholesterol.
P2860
Q34466077-0C8A1DBC-5F79-4650-88E0-6C849F24AC6CQ36409440-5E039F8B-1C7D-4D29-BE24-4C9023D13E6BQ37554404-9C8012FA-5254-4543-89C2-AB87D50D6148Q37780630-B57E0E35-6EA7-4C1B-9855-2F4868301139Q38168916-9754FDA1-F93D-4DD7-A658-5E21EF7B13F1Q38207946-29DECA54-AD2D-435D-B4D6-79549B0DC1D6Q38365744-3E2BC0C3-7008-4112-94C8-B614AB707952Q38975149-3DBBC92E-0CF7-40E7-9E30-FB3AD229F062Q42178673-AFBA11FA-AA27-45A8-87BE-E82E5A938E62Q44152031-0BE4AA3B-DD8F-4D10-8C12-7912A2D516E7Q45169346-197735F6-A3D9-4EBA-A61B-319277967F68Q47988623-00AAE0C2-F2D4-4337-A49A-28FAA17E97CDQ51739310-BD1512F5-8918-4F43-86D6-FB0C87CE0795Q51795535-963974BD-64E1-4051-A6DC-23C8366EA68AQ53630596-FF63347D-C41A-48D5-BF7C-9B49EB195D61
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Biomarkers of drug-induced vascular injury.
@ast
Biomarkers of drug-induced vascular injury.
@en
type
label
Biomarkers of drug-induced vascular injury.
@ast
Biomarkers of drug-induced vascular injury.
@en
prefLabel
Biomarkers of drug-induced vascular injury.
@ast
Biomarkers of drug-induced vascular injury.
@en
P2093
P1476
Biomarkers of drug-induced vascular injury
@en
P2093
Bjurstrom S
Foster-Brown L
P304
P356
10.1016/J.TAAP.2005.04.028
P433
P577
2005-09-01T00:00:00Z